View Older Stories View More Recent Stories

Oct 29, 2019 07:30AM Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
Oct 29, 2019 07:30AM Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
Oct 25, 2019 10:00AM Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
Oct 25, 2019 10:00AM Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
Sep 5, 2019 07:33AM Esperion Therapeutics (ESPR) Reports Complete Patient Enrollment in Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Sep 5, 2019 07:30AM Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Sep 5, 2019 07:30AM Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Aug 30, 2019 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 30, 2019 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 29, 2019 07:33AM Esperion Therapeutics (ESPR) Reports Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet
Aug 29, 2019 07:30AM Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
Aug 29, 2019 07:30AM Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
Aug 8, 2019 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
Aug 8, 2019 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
Aug 6, 2019 04:15PM Esperion to Present at the BTIG Biotechnology Conference
Aug 6, 2019 04:15PM Esperion to Present at the BTIG Biotechnology Conference
Jul 30, 2019 04:15PM Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
Jul 30, 2019 04:15PM Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
Jun 26, 2019 04:12PM Esperion Therapeutics (ESPR) and Oberland Capital Announce $200 Million Funding Agreement
Jun 26, 2019 04:10PM Esperion and Oberland Capital Announce $200 Million Funding Agreement
Jun 26, 2019 04:10PM Esperion and Oberland Capital Announce $200 Million Funding Agreement
May 30, 2019 04:30PM Esperion Therapeutics (ESPR) Names Tracy M. Woody to Board
May 30, 2019 04:15PM Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
May 30, 2019 04:15PM Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
May 28, 2019 07:00AM Esperion to Participate in Upcoming Investor Conferences
May 28, 2019 07:00AM Esperion to Participate in Upcoming Investor Conferences
May 10, 2019 08:00AM Esperion to Participate in Upcoming Investor Conferences
May 10, 2019 08:00AM Esperion to Participate in Upcoming Investor Conferences
May 8, 2019 07:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
May 8, 2019 07:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
May 7, 2019 05:30AM Esperion to Host Analyst and Investor Day Event on May 30
May 7, 2019 05:30AM Esperion to Host Analyst and Investor Day Event on May 30
May 6, 2019 06:25AM Esperion (ESPR) Announces U.S. FDA Acceptance of NDAs for Both Bempedoic Acid and Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
May 5, 2019 05:00PM Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
May 5, 2019 05:00PM Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
Apr 2, 2019 04:30PM Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
Apr 2, 2019 04:30PM Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
Apr 1, 2019 04:21PM Esperion Therapeutics (ESPR) Announces Publication in JAHA of Bempedoic Acid Study 3 Results
Apr 1, 2019 04:15PM Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
Apr 1, 2019 04:15PM Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
Mar 18, 2019 09:23AM Esperion Therapeutics (ESPR) Reports Phase 3 Results from Study 2 (1002-047, also known as CLEAR Wisdom) of Bempedoic Acid at ACC Meetings
Mar 18, 2019 09:20AM Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
Mar 18, 2019 09:20AM Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
Mar 13, 2019 05:05PM Esperion Therapeutics (ESPR) Announces Publication of Bempedoic Acid Study 1 Results in NEJM
Mar 13, 2019 05:05PM Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Mar 13, 2019 05:05PM Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Mar 4, 2019 04:30PM Esperion to Participate in Upcoming Investor Conferences
Mar 4, 2019 04:30PM Esperion to Participate in Upcoming Investor Conferences
Mar 4, 2019 08:17AM Esperion Therapeutics (ESPR) Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at ACC
Mar 4, 2019 08:00AM Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
View More Recent Stories View Older Stories